Five Ways to Leap Into Competitive Execution in Oncology

Posted by Namita Kalyan on Jan 10, 2018 8:00:00 AM

Scott Cohen co-wrote this blog post with Namita Kalyan.

You may have heard this old adage: Three frogs are sitting on a log. One of them decides to leap off. How many frogs are left on the log? The answer is still three frogs. There’s a difference between deciding to do something and actually doing it—and that difference is execution.


>
Read More

The Promise of CAR-T: Three Strategies for Getting Next-Wave Cancer Medicines to Patients in Need

Posted by Namita Kalyan on May 10, 2016 8:00:00 AM

After initial concerns and disappointing studies in the 1980s to early 2000s, cell and gene therapies are now at the forefront of medicine, displaying unprecedented efficacy in a number of clinical trials. As more trials occur, the patient success stories are growing, and an increasing number of manufacturers are investing or partnering to develop more of these next-wave cancer medicines. In 2015, close to 100 clinical trials involving CAR (chimeric antigen receptor) T-cell therapies were under development, according to the Journal of Immunology Research.


>
Read More